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ABSTRACT 
Objective 
To evaluate whether a nationwide prenatal anomaly screening programme improves detection 
rates of univentricular heart (UVH) and transposition of great arteries (TGA) and whether 
maternal risk factors for severe fetal heart disease affect prenatal detection. 
Design 
Population-based cohort study. 
Setting 
Nationwide data from Finnish registries 2004 to 2014. 
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Population 
642 456 parturients and 3449 terminated pregnancies due to severe fetal anomaly. 
Methods 
Prenatal detection rates were calculated in three time periods (prescreening, transition, and 
screening phase). The effect of maternal risk factors (obesity, in vitro fertilization, 
pregestational diabetes, and smoking) was evaluated. 
Main outcome measures 
Change in detection rates and impact of maternal risk factors on screening programme 
efficacy. 
Results 
In total 483 cases of UVH and 184 of TGA were detected. The prenatal detection rate of 
UVH increased from 50.4% to 82.8% and TGA from 12.3% to 41.0% (P<0.0001). Maternal 
risk factors did not affect prenatal detection rate, but detection rate differed substantially by 
region. 
Conclusions 
A nationwide screening programme improved overall UVH and TGA detection rates, but  
regional differences were observed. Obesity or other maternal risk factors did not affect the 
screening programme efficacy. The establishment of structured guidelines and 
recommendations are essential when implementing the screening programme. In addition, 
prospective screening register is highly recommended to ensure high quality of screening.  
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INTRODUCTION 
Critical congenital heart defects (CHD) are the most common congenital anomalies that may 
lead to infant death when undiagnosed.1-3 Prenatal detection of severe cardiac defects allows 
optimal follow up of pregnancy and delivery planning of a critically ill child and reduces 
mortality and morbidity.4-6 Heart defects such as univentricular heart (UVH) and transposition 
of the great arteries (TGA) benefit from prenatal diagnosis and should be prioritized in 
prenatal CHD screening.  
Prenatal ultrasound screening of congenital anomalies is recommended and widely 
implemented.7-9 Screenings are performed in the first (11 to 13 weeks of gestation) and 
second trimester (detailed structural anomaly screening at 18 to 22 gestational weeks).7-9 
National screening programmes of congenital structural anomalies are part of routine prenatal 
care in developed countries. Previous studies on the impact of anomaly screening 
programmes have examined regional cohorts;10-12 and nationwide data are scarce.13 Recent 
obstetrical ultrasound guidelines incorporate screening of cardiac outflow tracks and the four-
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chamber view to improve prenatal detection of critical cardiac outflow defects such as 
TGA.14-16 There is limited knowledge on whether maternal risk factors that expose offspring 
to increased risk of critical CHD17,18 affect the prenatal detection of fetal CHD.19  
 
We hypothesise that implementation of a nationwide anomaly screening programme 
improves prenatal detection rates and may affect the live birth prevalence of UVH and TGA. 
As a secondary outcome, we evaluated if maternal risk factors for fetal CHD (obesity, in vitro 
fertilisation [IVF], pregestational diabetes, and smoking) impact prenatal screening 
programme efficacy.   
 
METHODS  
Screening programme. A recommendation on fetal anomaly screening was given by the 
Finnish Ministry of Social Affairs and Health in 1999. The considerable heterogeneity of 
examinations raised concern about the quality and reliability of the screening; an expert 
committee established new official recommendations. The nationwide screening programme 
for fetal anomalies was introduced in Finland in January 2007. A new decree came into effect 
in January 2010 that required all municipalities to offer a screening of congenital anomalies 
for all pregnant women. A transition period from 2007 to 2009 was given to organise the fetal 
screening in every municipality in Finland. Screening is voluntary and free of charge and 
includes first-trimester ultrasound, combined screening for chromosomal defects, and second-
trimester ultrasound (programme described in detail in Figure S1). The expert committee 
recommended systematic, ongoing auditing of screening personnel and establishment of a 
prospective screening register. These recommendations have not been implemented.  
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Cardiac anatomy assessment is not included in first-trimester ultrasound. The second-
trimester ultrasound includes four-chamber view (situs, axis, size and symmetry of the 
chambers, heart rate, av-valves) and outflow track view (and crossing of the great arteries) as 
recommended in recent international ultrasound guidelines. 14-16 However, the three-vessel 
view is not included in the screening requirements. The fetal ultrasound screening protocol is 
shown in Table S1 and equipment recommendations in Table S2. Examinations are mainly 
performed by trained midwives. The training programme is shown in Table S3. If an 
abnormality is suspected, the patient is referred to a perinatologist or a fetal cardiologist for a 
detailed fetal echocardiogram. Women with an increased risk for a fetal CHD are usually 
referred directly to a perinatologist or a fetal cardiologist.
16
 
 
Comparison of time periods were prescreening phase (2004 to 2006), transition phase (2007 
to 2009), and screening phase (2010 to 2014). No reliable data are available on how 
screening was organized in practice from 2004 to 2006. During the transition period (2007 to 
2009), screening personnel were trained as recommended in the guidelines. Combined first-
trimester screening was offered to 58% to 87% and second-trimester structural screening to 
77% to 88% of all pregnant women in 2007 to 2009. Since 2010, all pregnant women have an 
equal opportunity to participate in fetal screening performed by trained personnel with high-
quality equipment. Since the initial status of prenatal ultrasound screening varied between 
different regions of Finland, we evaluated the change in prenatal detection rate as the 
outcome of the effectiveness of implementation of nationwide screening. Regional data 
suggest that approximately 95% of pregnant women participate in ultrasound screening 
during pregnancy. In Finland, all pregnancies with antenatally detected critical CHD are 
referred for delivery and early neonatal surgery exclusively to Helsinki University Hospital. 
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Classification of heart defects. We selected UVH as an index cardiac anomaly for the four-
chamber view and  TGA for the outflow track view. From 642 456 parturients, 651 969 
children were born of which 649 971 children were born alive (National Medical Birth 
Register) during the study period from 2004 to 2014; 3449 pregnancies were terminated due 
to severe fetal anomaly (Finnish Register of Congenital Malformations). UVH classification 
includes hypoplastic left heart syndrome (HLHS) and other types of UVH; and TGA is 
classified as simple with or without ventricular septal defect (VSD) and more complex forms. 
A detailed morphological classification of heart defects is shown in Table S4. Borderline 
cases of UVH, if operated postnatally following a two-chamber line, were excluded.  
 
Classification of primary outcome; prenatal detection. Data were divided according to 
prenatal diagnosis (yes/no). We assessed all prenatally detected index cases and considered 
whether they were detected within or outside (random diagnosis) the screening programme. 
We further evaluated the number of late prenatal diagnoses (diagnosis after 24+0 gestational 
weeks; e.g., due to suboptimal imaging of four-chamber or outflow track views of the heart 
leading to follow-up ultrasound and delayed confirmation of CHD). The cut-off for late 
diagnosis was set at the latest possible legal pregnancy termination gestational age (24+0 
weeks of gestation) allowed for a severe fetal anomaly. 
  
Register data. Study data were collected from national registers containing information on 
all births, stillbirths, and pregnancy terminations due to fetal anomaly, including all pre- and 
postnatally diagnosed cases of UVH and TGA. The national registers are comprehensive: 1) 
the National Register of Paediatric Cardiac Surgery maintained by Children’s Hospital at 
Helsinki University Hospital and the registers at the National Institute for Health and 
Welfare; 2) the Finnish Register of Congenital Malformations; 3) the Register of Induced 
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Abortions; 4) the Medical Birth Register; and the 5) Cause-of-Death Register, maintained by 
Statistics Finland.  
 
The Finnish Register of Congenital Malformations actively collects data on all 
fetal/congenital malformations in Finland.
20
 We cross-checked data with the mothers’ and 
live born infants’ identification numbers and verified all information from hospital records, 
including prenatal and postnatal reports, karyotype, and autopsy results. One paediatric and 
fetal cardiologist (TO) confirmed all cardiac diagnoses and one clinical geneticist (AR) 
confirmed all extra-cardiac malformations. Major extra-cardiac malformations were included 
according to EUROCAT guidelines.
21
 
 
Prevalence and maternal risk factors. The total and live birth prevalence was calculated 
according to EUROCAT guidelines.
22
 We determined the national and regional total and live 
birth prevalence of UVH and TGA. Finland is divided into five university hospital districts 
(city in brackets): southern (Helsinki), central (Tampere), western (Turku), eastern (Kuopio), 
and northern (Oulu). The mothers’ municipality of residence was used to identify the correct 
region. 
  
Maternal characteristics are shown in Table 1. We analysed the following previously known 
maternal risk factors for fetal CHD: obesity, pregestational diabetes, multiple pregnancies, 
IVF, and smoking in the study population (in births). The official national recommendation 
for folic acid supplementation for all women planning pregnancy was introduced only in 
2016; the registers lack this information. BMI was calculated from register data of height and 
pregestational weight recorded on the first prenatal visit on gestational week 8. BMI ≥ 30 
was considered obese. Data on maternal BMI were accessible in 89% (355/400) of 
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parturients in our cohort (birth cohort) and in 95% (608 731/642 456) of all parturients. The 
mother was considered a smoker even if she ceased smoking during the first trimester. These 
risk factors were compared to the national Medical Birth Register data of all parturients 
(n=642 456) over the study period. The data on chorionicity in multiple pregnancies were 
collected from year 2017 and are hence lacking over studied period. IVF data include 
parturients with IVF, intracytoplasmic sperm injection (ICSI), or frozen embryo transfer 
(FET) treatment. The incidence of pregestational diabetes was calculated. The Medical Birth 
Register data of diabetes are collected for all births from the year 2006 onwards (all 
parturients 2006 to 2014; n=528 618); these years were used to assess pregestational diabetes 
incidence. The differences in risk factors between mothers with and without a prenatal 
diagnosis were evaluated. 
 
Statistics.  Data analyses were performed with IBM SPSS version 22. A one-sample t-test 
was used to test if the difference in means was statistically significant between our sample 
and national data according to the Medical Birth Register. Frequencies and percentages were 
used to describe categorical variables. The chi-square test, the test for relative proportions, 
and Fisher’s exact test were used for statistical comparisons. We considered P< 0.05 as 
statistically significant. All tests were two-sided. 
 
Core outcome sets were not used and patients were not involved. The funding of this research 
was only as personal working grants for the corresponding author.    
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RESULTS 
A total of 642 456 births (National Medical Birth Register) were registered and 483 UVH and 
184 TGA cases were diagnosed during the study period (2004 to 2014). The majority of cases 
were singletons, 3.9% (26/667) of all and 5.0% (20/400) of births with CHD were twins, and 
0.3% (2/667) and 0.5% (2/400) were triplets, respectively. A flowchart of the data and 
prenatal diagnosis of UVH and TGA are shown in Figure 1. The assessed maternal 
demographics are shown in Table 1. Chromosomal anomalies observed in the cohort are 
listed in Table S5. 
 
Impact of the initiation of the national prenatal screening programme and the 
prevalence of heart defects 
 
Univentricular heart. Implementation of the nationwide screening programme improved the 
prenatal detection rates of UVH significantly from 50.4% (63/125; prescreening phase) to 
66.7% (84/126; transition phase) and 82.8% (192/232; screening phase) (the total change 
32.4%, 95% CI 18.5–49.0; P<0.0001). The changes in regional prenatal detection rates 
during the study period are shown in Table 2. Random diagnoses (detected outside the 
screening programme) decreased over the study period (Table 2). These random diagnoses 
were excluded from the analysis of the screening programme impact. The rate of late 
diagnoses (after 24+0 gestational weeks) did not change over the study period (Table 2). In 
49 cases, UVH was detected before second-trimester structural screening; 77.6% (38/49) of 
these cases had other major extracardiac anomalies or chromosomal anomalies. Distribution 
of gestational age at prenatal detection is shown in Figure S2a. 
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The overall national total prevalence of all UVH was 7.41/10 000 births (over the study 
period) and 3.74/10 000 births for a subgroup of HLHS. The live birth prevalence of all UVH 
was 3.39/10 000 and of HLHS 1.87/10 000 live births. While the live birth prevalence of all 
UVH decreased from 4.48/10 000 (prescreening phase) to 2.90/10 000 (screening phase) 
(P=0.005), the total national prevalence did not change over the study period (7.16/10 000 to 
7.79/10 000; P=0.448). Differences in the total prevalence of UVH did not vary by region 
(range 6.80/10 000 to 8.48/10 000, P=0.405) (Figure 2a). The pregnancy termination rate in 
UVH cases increased significantly from 35.2% (44/125; prescreening phase) to 60.8% 
(141/232; screening phase); total change was 25.6% (95% CI 14.8–35.5; P<0.0001). 
 
Transposition of great arteries. Implementation of the nationwide screening programme 
improved the detection rate of TGA significantly from 12.3% (7/57; prescreening phase) to 
20.4% (10/49; transition phase) and to 41.0% (32/78; screening phase) (the total change 
28.7%, 95% CI 7.2–74.0; P<0.0001). Changes in the regional prenatal detection rates during 
the study period are shown in Table 2. Random diagnoses decreased significantly over the 
study period (Table 2). These random diagnoses were excluded from the analysis of the 
screening programme impact. The rate of late diagnoses (after 24+0 gestational weeks) did 
not change over the study period (Table 2). Only five cases were found before second-
trimester structural screening; all these cases had other major extracardiac anomalies. 
Distribution of the weeks of gestation at prenatal detection is shown in Figure S2b. 
 
The overall total prevalence of TGA in Finland was 2.82/10 000 births and the live birth 
prevalence was 2.55/10 000 live births. The national total prevalence (range from 3.26/10 
000 to 2.62/10 000; P=0.201) and live birth prevalence (range 3.04/10 000 to 2.40/10 000; 
P=0.18) did not change over the study period. However, the total prevalence of TGA varied 
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significantly between the western (2.07/10 000) and eastern (3.92/10 000) (P=0.018) regions 
(Figure 2b). Pregnancy termination rates in TGA cases did not change significantly (5.3% 
[5/57], prescreening phase to 9.0% [7/78], screening phase; total change 3.7% [95% CI -6.5–
12.8]; P=0.416). Most terminated cases had other major extra-cardiac malformations. 
 
Maternal risk factors for heart defects and the impact of risk factors for the screening 
programme.   
No associations between prenatal diagnoses and any of the studied maternal risk factors were 
observed (obesity, P=0.61; pregestational diabetes, P=0.34; IVF, P=0.54; multiple pregnancy, 
P=0.09; smoking, P=0.60). The studied maternal risk factors for heart defects in the CHD 
birth cohort and comparison with all parturient population are reported in Table 3. There was 
no difference in the mean BMI (25.5±6.0 versus 25.4±5.2; P=0.850) between mothers with or 
without a prenatal diagnosis. Women expecting an infant with UVH or TGA were obese 
more frequently compared with parturients (P=0.007). The results were consistent after 
excluding mothers with pregestational diabetes or mothers with fetuses with chromosomal 
defects. Pregestational diabetes was more common among the cohort than in all parturients 
(P<0.0001). No difference in the frequency of IVF treatment was observed between the CHD 
birth cohort and all parturients. However, after including pregnancy terminations, 
pregnancies conceived after IVF were significantly more common (P=0.005) in the CHD 
cohort than in the all parturients population. These results were consistent after excluding 
cases with chromosomal defects (P=0.03). The number of twin and triplet pregnancies was 
significantly higher in CHD cohort than in the all parturient population, although no 
difference in IVF treatment was observed in these subgroups.  
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DISCUSSION 
Statement of principal findings 
The implementation of a nationwide systematic fetal anomaly screening programme 
significantly improved prenatal detection of UVH and TGA. Ultrasound screening of the fetal 
heart includes the four-chamber view and the outflow tract areas; UVH and TGA were used 
as index markers, respectively. The studied maternal factors associated with the risk of fetal 
CHD did not affect prenatal detection. Importantly, there were still significant variations in 
detection rates within the country. Previous information on the efficacy of national screening 
programmes and national prevalence of critical CHDs is limited due to the lack of 
comprehensive national registers of congenital anomalies and incomplete data on 
terminations, stillbirths, and live births. Data from a prospective screening register might 
enable further improvement of the prenatal detection rate in low detection areas. This is 
essential since prenatal diagnosis decreases perinatal mortality and morbidity in transposition 
of the great arteries. 
4
 Children born with prenatally diagnosed UVH are hemodynamically 
more stable than those detected postnatally, 
5,6
 and detection in screening allows the option of 
termination as only palliative care is available. 
 
Strengths and limitations  
This study has several strengths. First, we controlled and confirmed all diagnoses from 
patient records by a fetal and paediatric cardiologist and reviewed all potential cases with 
diagnoses leading to UVH or TGA. Second, Finnish registries are comprehensive as is 
mandatory to report data on every birth and pregnancy termination. The registers are 
overlapping; every case in the Finnish Register of Congenital Malformations was also found 
in the Medical Birth Register or the Register on Induced Abortions. We avoided double-
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counting by using the unique identification numbers available in all registers. The Finnish 
Register of Congenital Malformations is a unique database and receives reports from every 
pre- or postnatally detected congenital anomalies and actively collects data from all cases 
found in other registers. This study also has some limitations. Although recommended by the 
expert committee, a prospective screening register has not been established due to budget 
restrictions. Due to the lack of a screening register, we do not have data on screening 
personnel, equipment, or structurally collected data on the findings. Structurally collected 
data would enable an analysis of the reasons behind regional variation. While exact national 
numbers are not accessible, approximately 95% of pregnant women participate in ultrasound 
screening during pregnancy. Finally, terminations did not include data on BMI, smoking, or 
maternal diagnoses. 
 
Interpretation 
In our nationwide study, the prenatal detection rate of UVH increased from 50.4 % to 82.8% 
after implementing the nationwide screening programme. The results are similar to reports 
from regional cohorts in the Czech Republic (from 33.6% to 83.2%)
10
 and The Netherlands 
(from 55.3% to 93.6%)
11
 and from recent nationwide data from Denmark (34.3% to 
83.3%).
13
 In our study, prenatal detection rates of TGA increased from 12.3% to 41.0%. 
These results were better than those in the Czech cohort (from 5.7% to 25.6%),
10
 and similar 
to those in the Dutch cohort (from 18.6% to 48%)
11
 and Danish cohort (4.3% to 41.0%).
13
 All 
these programmes included structural anomaly screening between gestational weeks 18 to 20 
to 22. In the Czech Republic, screening is performed by trained local 
obstetricians/gynaecologists and in The Netherlands mainly by trained ultrasonographers. 
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Although regional variations were seen, implementing a nationwide screening programme 
improved the antenatal detection rates of UVH significantly in all parts of the country 
regardless of initial detection rates before implementation. Similarly, the prenatal detection of 
TGA increased significantly nationwide. However, there was significant variation within the 
country. TGA is a rare anomaly and detection rates changed only modestly in the areas where 
the total prevalence of TGA was low. This minor change may be due to the limited number 
of cases in these regions and the difficulties in identifying this anomaly.
23
 The screening and 
education criteria for the screening personnel are based on national recommendations. 
However, every municipality can decide whether to develop the service by training personnel 
or to obtain the service from private providers. Finally, some effect on the improvement of 
anomaly detection rates may be due to developments in ultrasound equipment during the 
study period. The lack of a prospective screening register prevented us from investigating the 
reasons behind the observed regional variations and how expert committee recommendations 
were fulfilled. 
The total prevalence of UVH was 7.4/10 000 and is higher than previously reported (3.4/10 
000 to 5.3/10 000).
13,24,25
 In our study, one fetal cardiologist meticulously evaluated all fetal 
echocardiograms and autopsy reports. We included every diagnosed case over the study 
period, even terminated cases with chromosomal anomalies (15.6%) and cases with 
ultrasound detection but without autopsy confirmation. Previously, these cases or pregnancy 
terminations were excluded, or reference to inclusion criteria was missing.
24,26-28
 
Interestingly, the live birth rate of UVH was also higher in Finland (2.9/10 000 live births; 
screening phase), than in Denmark (0.8/10 000)
24
 and the Paris region (1.5/10 000).
25
 In our 
cohort, termination of pregnancy due to UVH occurred in 52% of cases; the corresponding 
values were 44.8% in Denmark 
13
 and 62.7% in Paris.
25
 These results may indicate that the 
total prevalence of UVH in Finland may be higher than in Europe overall. A similar 
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difference is seen in the total prevalence and live-birth prevalence of severe CHD (34.9/10 
000 and 28.1/10 000, respectively, according to the Finnish Register of Congenital 
Malformations) when compared with The Netherlands (27/10 000 and 20/10 000, 
respectively). The total and live birth prevalence of TGA (2.82/10 000 and 2.55/10 000, 
respectively) were consistent with those previously reported (2.0 to 3.5/10 000).
4,13,29,30
   
In our study, obesity or other maternal risk factors did not affect prenatal detection. Previous 
studies have shown that maternal obesity is a risk factor for fetal congenital heart defects
31-33
 
and mothers without a prenatal diagnosis were more obese than mothers with prenatal 
diagnosis.
19
 Suboptimal cardiac views in second-trimester ultrasound are common in obese 
women.
34
 In our study, there were no differences in maternal characteristics or risk factors 
between those with and without a prenatal diagnosis. Late or random diagnoses were not 
more common in obese women. However, it must be noted that the BMI data of terminated 
pregnancies are missing and this can affect the results in the UVH cohort due to the high 
proportion of terminations. However, we did not observe any difference in the TGA cohort in 
which terminations were few. Pregestational diabetes leads to more thorough follow up and a 
higher prenatal detection rate of congenital anomalies.
35
 We did not observe a significant 
difference in prenatal detection of UVH and TGA among mothers with pregestational 
diabetes; the numbers were, however, limited. In agreement with previous studies,
36
 CHD 
was associated with multiple pregnancies. A recent meta-analysis suggests that IVF treatment 
increases the risk of CHD.
37
 Similarly, we observed an association between IVF and CHD 
when the whole cohort (including pregnancy terminations) was studied. However, no 
association between IVF and CHD was detected in the birth cohort or the cohort of multiple 
pregnancies. The latter is probably due to one-embryo transfer that is primarily applied in 
Finland. Interestingly, multiple pregnancies or IVF treatment did not increase prenatal 
detection even though these pregnancies are often followed more thoroughly. 
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CONCLUSIONS 
The implementation of nationwide prenatal anomaly screening significantly improves the 
prenatal detection of UVH and TGA. The establishment of a prospective screening register is 
strongly recommended to ensure high quality of screening. The total and live birth rates of 
UVH were higher in Finland than previously reported. The total and live birth rates of TGA 
were consistent with previous reports. Obesity or other maternal risk factors for severe fetal 
heart disease did not affect prenatal detection.  
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Figure legends 
Figure 1. Prenatal detection rates, extra-cardiac malformations, and chromosomal defects in 
a) UVH and b) TGA. (UVH=univentricular heart, HLHS=hypoplastic left heart syndrome, 
TGA=transposition of great arteries, TOPFA= Termination of Pregnancy due to Fetal 
Anomaly) 
 
Figure 2. Regional total prevalence (/10 000 births) in five university hospital districts and 
prenatal detection rates (%) in screening phase 2010 to 2014 of a) UVH and b) TGA 
 
Table legends 
Table 1. Clinical characteristics of all mothers. 
 
Table 2. Prenatal detection rates and change after implementation of systematic screening 
(random prenatal diagnoses excluded) and rates in random and late diagnoses comparing the 
first and last study periods 
 
Table 3. Comparison of heart anomaly risk factors in birth cohort (mothers of children born 
with a congenital heart defect) and all parturient population in study period. 
 
Supplementary material legends 
Table S1. Screening protocol for first-trimester and second-trimester ultrasound 
Table S2. Minimum and preferable ultrasound equipment requirements (The Royal College 
of Radiologists, 2005) 
Table S3. Training modules for fetal screening personnel 
Table S4. Distribution of detected heart anomalies  
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Table S5. Chromosomal anomalies in cases with univentricular heart and transposition of 
great arteries.  
 
Figure S1. Flowchart of the systematic fetal screening protocol in Finland
38
.  
Figure S2. Timing of total prenatal detection of a) univentricular heart and b) transposition of 
great arteries over the study period. Cut-off delayed diagnosis marked with a horizontal line 
and study periods with vertical lines: prescreening phase, transition phase and screening 
phase. 
 
 
Table 1. Clinical characteristics of all mothers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mothers 
 
 Total time period 2004 to 
2014 
UVH (n=483) 
TGA (n=184) 
All parturients (n=642 456) 
Maternal age a 
(years) 
 
UVH 30.7±5.7 
TGA 30.2±5.2 
All 
parturientsc  
30.1±5.4 
Previous 
pregnancies (n) b 
 
UVH 1(1-2) 
TGA 1(0-2) 
All 
parturientsc  
1(0-2) 
Previous births 
(n) b 
 
UVH 1(0-2) 
TGA 1(0-2) 
All 
parturients c 
1(0-1) 
BMI a 
 
UVHc 25.7±5.8* 
TGAc 25.1±5.1** 
All 
parturientsc 
24.3±4.8  
a=Mean (SD)  
b=Median (IQR range, 25-75%) 
c=only births included (UVH n=232, TGA n=168) 
* compared to all parturient group, P=0.0006 
** compared to all parturient group, P=0.05 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2. Cases and prenatal detection rates and change after implementation of systematic 
screening (random prenatal diagnoses excluded) and rates in random and late diagnoses comparing 
the first and last study periods.  
 
Region Prenatal detection 
rate prescreening 
period   
Prenatal detection 
rate screening period  
P-value 
 UVH TGA UVH TGA UVH TGA 
National 
 
50.4%  
63/125 
12.3% 
7/57 
82.8% 
192/232 
 
41.0% 
32/78 
<0.0001 <0.0001 
Southern 
 
57.4% 
27/47 
4.8% 
1/21 
85.1% 
57/67 
37.0% 
10/27 
0.001 0.008 
Northern 
 
57.1% 
12/21 
25.0% 
2/8 
82.1% 
32/39 
53.3% 
8/15 
0.04 0.19 
Central 
 
47.4% 
9/19 
10.0% 
1/10 
81.0% 
47/58 
18.2% 
2/11 
0.004 0.59 
Western 
 
33.3% 
7/21 
22.2% 
2/9 
67.9% 
19/28 
12.5% 
1/8 
0.02 0.60 
Eastern 
 
47.1% 
8/17 
11.1% 
1/9 
 
92.5% 
37/40 
64.7% 
11/17 
0.0001 0.009 
Random 
diagnoses 
of all diagnoses  
(national) 
8.7% 
6/69 
22.2% 
2/9 
 
3.0% 
6/198 
3.0% 
1/33 
0.05 0.048 
Late diagnoses 
of screening 
diagnoses 
(national) 
1.6% 
1/63 
14.3% 
1/7 
6.8% 
13/192 
12.5% 
4/32 
0.12 0.90 
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Table 3. Comparison of heart anomaly risk factors in birth cohort (mothers of children born 
with a congenital heart defect) and all parturient population in study period.  
  
 
  
 Cohort % All parturients % P-value 
BMI ≥ 30 16.6%  
(59/355) 
11.9% 
(72739/608731) 
0.007 
Pregestational 
diabetes* 
2.9% 
(10/340) 
0.8% 
(3996/528618) 
<0.0001 
Smoking  16.2% 
(54/333) 
15.5% 
(97241/626811) 
0.72 
IVF treatment 2.8% 
(11/400) 
2.3% 
(14579/642456) 
0.52 
multiple 
pregnancies 
5.5% 
(22/400) 
1.5% 
(9393/642456) 
<0.0001 
twins 5.0% 
(20/400) 
1.4% 
(9272/642456) 
<0.0001 
triplets 0.5% 
(2/400) 
0.02% 
(120/642456) 
<0.0001 
IVF in multiple 
pregnancies 
13.6% 
(3/22) 
14.5% 
(1363/9393) 
0.87 
*data from2006 to 2014 
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